Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States
The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.
Tipranavir (Aptivus, TPV)
Last Updated: December 7, 2018; Last Reviewed: December 7, 2018
Excerpt from Table 8
|Formulation||Dosing Recommendationsa||Use in Pregnancy|
Note: Must be combined with RTV for PK boosting
|Standard Adult Dose:
Dosing in Pregnancy:
PK in Pregnancy:
|TPV should not be used during pregnancy.
Moderate placental transfer to fetus reported in 1 patient.b
Insufficient data to assess for teratogenicity in humans. No evidence of teratogenicity in rats or rabbits.
Must be given as low-dose RTV-boosted regimen.
a Individual ARV drug dosages may need to be adjusted in patients with renal or hepatic insufficiency (for details, see the Adult and Adolescent Guidelines Appendix B, Table 8).
Key to Acronyms:]PK = pharmacokinetic; RTV = ritonavir; TPV = tipranavir; TPV/r = tipranavir/ritonavir
- AIDSinfo Drug Database
- AIDSinfo Patient Materials: Preventing Mother-to-Child Transmission of HIV
- AIDSinfo Patient Materials: HIV Medicines During Pregnancy and Childbirth
- AIDSinfo Patient Materials: Protecting Baby from HIV
- AETC National HIV Curriculum
- How to Cite These Guidelines
- Perinatal Guidelines Archive